Tags

Type your tag names separated by a space and hit enter

Pharmacologic treatment of obsessive-compulsive disorder: comparative studies.
J Clin Psychiatry. 1997; 58 Suppl 12:18-22.JC

Abstract

The predominant hypothesis about obsessive-compulsive disorder (OCD) pathophysiology implicates abnormal serotonergic function regulation. Pharmacologic agents with potent serotonin reuptake-inhibiting properties have demonstrated effectiveness in treating OCD. In short-term clinical trials compared by meta-analysis, clomipramine and serotonin selective reuptake inhibitors (SSRIs) were found superior to placebo in improving symptoms of OCD. In one-to-one comparative studies, clomipramine has been found as efficacious as fluoxetine and fluvoxamine, and in a comparative trial of clomipramine with sertraline, there was a statistically superior response to sertraline after 16 weeks of treatment; moreover, discontinuation rate in patients taking clomipramine was more than twice that in patients taking sertraline (26% vs. 11%). In contrast to patients receiving clomipramine who showed poor tolerance in long-term use, patients maintained on fluoxetine for 24 weeks after an acute phase well tolerated the medication. In another study, patients responding to 12 weeks of sertraline treatment also showed improved tolerance during an additional 40-week period, with 75% completing the continuation phase. With long-term or even lifelong treatment appearing necessary for people with OCD, those agents that result in better tolerance will prove preferable.

Authors+Show Affiliations

INSERM U302, Hôpital La Salpêtrière, Paris, France.No affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

9393392

Citation

Flament, M F., and J C. Bisserbe. "Pharmacologic Treatment of Obsessive-compulsive Disorder: Comparative Studies." The Journal of Clinical Psychiatry, vol. 58 Suppl 12, 1997, pp. 18-22.
Flament MF, Bisserbe JC. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies. J Clin Psychiatry. 1997;58 Suppl 12:18-22.
Flament, M. F., & Bisserbe, J. C. (1997). Pharmacologic treatment of obsessive-compulsive disorder: comparative studies. The Journal of Clinical Psychiatry, 58 Suppl 12, 18-22.
Flament MF, Bisserbe JC. Pharmacologic Treatment of Obsessive-compulsive Disorder: Comparative Studies. J Clin Psychiatry. 1997;58 Suppl 12:18-22. PubMed PMID: 9393392.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacologic treatment of obsessive-compulsive disorder: comparative studies. AU - Flament,M F, AU - Bisserbe,J C, PY - 1997/1/1/pubmed PY - 1997/12/11/medline PY - 1997/1/1/entrez SP - 18 EP - 22 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 58 Suppl 12 N2 - The predominant hypothesis about obsessive-compulsive disorder (OCD) pathophysiology implicates abnormal serotonergic function regulation. Pharmacologic agents with potent serotonin reuptake-inhibiting properties have demonstrated effectiveness in treating OCD. In short-term clinical trials compared by meta-analysis, clomipramine and serotonin selective reuptake inhibitors (SSRIs) were found superior to placebo in improving symptoms of OCD. In one-to-one comparative studies, clomipramine has been found as efficacious as fluoxetine and fluvoxamine, and in a comparative trial of clomipramine with sertraline, there was a statistically superior response to sertraline after 16 weeks of treatment; moreover, discontinuation rate in patients taking clomipramine was more than twice that in patients taking sertraline (26% vs. 11%). In contrast to patients receiving clomipramine who showed poor tolerance in long-term use, patients maintained on fluoxetine for 24 weeks after an acute phase well tolerated the medication. In another study, patients responding to 12 weeks of sertraline treatment also showed improved tolerance during an additional 40-week period, with 75% completing the continuation phase. With long-term or even lifelong treatment appearing necessary for people with OCD, those agents that result in better tolerance will prove preferable. SN - 0160-6689 UR - https://www.unboundmedicine.com/medline/citation/9393392/Pharmacologic_treatment_of_obsessive_compulsive_disorder:_comparative_studies_ L2 - http://www.psychiatrist.com/jcp/article/pages/1997/v58s12/v58s1204.aspx DB - PRIME DP - Unbound Medicine ER -